SCHEMBL25422243

SCHEMBL25422243

COC(=O)c1ccc(=O)n(CC(C)C)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.58
GAA P10253 2/20 0.56
KDM4E B2RXH2 1/20 0.56
IDH1 O75874 1/20 0.42
MAPT P10636 4/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK10 P53779 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA12 O43570 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
BRD4 O60885 1/20 0.40
BRD2 P25440 1/20 0.40
BRD3 Q15059 1/20 0.40
BRDT Q58F21 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15024022 0.89 LMNA (0.57) LMNAGAAKDM4EIDH1MAPT
SCHEMBL14407026 0.89 LMNA (0.57) LMNAGAAKDM4EIDH1MAPT
SCHEMBL29169075 0.88 LMNA (0.56) LMNAGAAKDM4EIDH1MAPT
SCHEMBL25075523 0.88 LMNA (0.56) LMNAGAAKDM4EIDH1MAPT
SCHEMBL31132900 0.86 LMNA (0.57) LMNAGAAKDM4EIDH1MAPT
SCHEMBL1255539 0.82 LMNA (0.62) LMNAGAAKDM4EIDH1MAPT
SCHEMBL924099 0.82 B3GNT2 (0.44) LMNAKDM4EMAPTALDH1A1BRD4
SCHEMBL23562090 0.82 LMNA (0.62) LMNAGAAKDM4EIDH1MAPT
SCHEMBL25604578 0.81 BRD4 (0.61) LMNAGAAMAPTALDH1A1BRD4
SCHEMBL19190708 0.81 LMNA (0.61) LMNAGAAKDM4EIDH1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS PROTHENA BIOSCIENCES INC 2025-02-27 US disclosed
CN-118843626-A Heterocyclic compounds as DYRK1A inhibitors 普罗塞纳生物科学有限公司 2024-10-25 CN disclosed
EP-4444421-A2 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS Prothena Biosciences Limited (IE) 2024-10-16 EP disclosed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS DYRK1A, DYRK2, DYRK1B LMNA 4067/4885GAA 715/4885KDM4E 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.